PubRank

Shinichiro Tada

Author PubWeight™ 23.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002 6.72
2 Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res 2004 1.17
3 Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int J Oncol 2005 0.90
4 Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J Gastroenterol Hepatol 2007 0.90
5 Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepatogastroenterology 2005 0.89
6 A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis. J Gastroenterol 2009 0.88
7 Hepatocellular carcinoma in Keio affiliated hospitals--diagnosis, treatment, and prognosis of this disease. Keio J Med 2009 0.88
8 Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008 0.87
9 DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8. Cancer Sci 2010 0.85
10 Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006 0.85
11 The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C. J Interferon Cytokine Res 2002 0.83
12 Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection. PLoS One 2011 0.83
13 Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. J Med Virol 2008 0.81
14 A free radical scavenger, edaravone, attenuates steatosis and cell death via reducing inflammatory cytokine production in rat acute liver injury. Free Radic Res 2003 0.81
15 Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol 2004 0.80
16 Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase. Leuk Lymphoma 2006 0.79
17 Contribution of Irf-1 promoter polymorphisms to the Th1-type cell response and interferon-beta monotherapy for chronic hepatitis C. Hepatol Res 2005 0.79
18 Value of computed tomography-derived estimated liver volume/standard liver volume ratio for predicting the prognosis of adult fulminant hepatic failure in Japan. J Gastroenterol Hepatol 2005 0.78
19 Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo. Int J Oncol 2006 0.78
20 Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis. J Gastroenterol 2006 0.78
21 Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo) 2010 0.77
22 Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. Keio J Med 2006 0.76
23 On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. World J Gastroenterol 2010 0.75
24 Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta. Hepatogastroenterology 2006 0.75
25 Genomic mutations with amino acid substitutions of circulating hepatitis B virus found in non-B, non-C patients with hepatocellular carcinoma. Intern Med 2003 0.75